Abstract
Abstract 2478
Poster Board II-455
It is estimated that Asian Indian and Pakistani (AIP) comprises about 1.5% of the total US population and is rapidly growing. Hematological malignancies account for about 15% of all the cancers diagnosed in this group. The aim of this study is to analyze epidemiologic and survival parameters of common hematological malignancies in AIP living in the USA and compare it to the US White (USW) population for the first time.
The SEER (Surveillance Epidemiology and End results) database has been reporting cancer incidence since 1973. AIP with cancer diagnosis was reported separately under race and ethnicity in SEER database from 1988. Using SEER database 1988-2006, appropriate frequency and survival sessions (Kaplan-Meier survival method) were performed and epidemiologic characteristics for common hematological malignancies were compared between AIP and USW.
Variabales . | AIP . | USW . | P value . | Variables . | AIP . | USW . | P value . |
---|---|---|---|---|---|---|---|
Reported cases | 4.5% | 4% | NS | Stage IV | 58% | 50% | <0.01 |
Median age in yr | 52 | 67 | <0.001 | 1 yr survival | 85% | 78% | <0.01 |
Age < 65 at diagnosis | 59% | 47% | <0.001 | 2 yrs survival | 81% | 70% | <0.001 |
Age > 65 at diagnosis | 41% | 53% | <0.001 | 3 yrs survival | 76% | 65% | <0.001 |
Stage I/II | 16% | 32% | <0.001 | 4 yrs survival | 71% | 59% | <0.001 |
Stage III | 26% | 18% | <0.001 | 5 yrs survival | 70% | 56% | <0.001 |
Variabales . | AIP . | USW . | P value . | Variables . | AIP . | USW . | P value . |
---|---|---|---|---|---|---|---|
Reported cases | 4.5% | 4% | NS | Stage IV | 58% | 50% | <0.01 |
Median age in yr | 52 | 67 | <0.001 | 1 yr survival | 85% | 78% | <0.01 |
Age < 65 at diagnosis | 59% | 47% | <0.001 | 2 yrs survival | 81% | 70% | <0.001 |
Age > 65 at diagnosis | 41% | 53% | <0.001 | 3 yrs survival | 76% | 65% | <0.001 |
Stage I/II | 16% | 32% | <0.001 | 4 yrs survival | 71% | 59% | <0.001 |
Stage III | 26% | 18% | <0.001 | 5 yrs survival | 70% | 56% | <0.001 |
Variabales . | AIP . | USW . | P value . | Variables . | AIP . | USW . | P value . |
---|---|---|---|---|---|---|---|
Reported cases | 1.3% | 1.5% | NS | Stage IV | 37% | 29% | <0.01 |
Median age in yr | 31 | 38 | <0.01 | 1 year survival | 81% | 75% | <0.01 |
Age < 35 at diagnosis | 62% | 51% | <0.001 | 2 years survival | 79% | 66% | <0.001 |
Age > 35 at diagnosis | 38% | 49% | <0.001 | 3 years survival | 72% | 61% | <0.001 |
Stage I/II | 20% | 35% | <0.001 | 4 years survival | 68% | 57% | =0.001 |
Stage III | 43% | 36% | <0.001 | 5 years survival | 66% | 53% | =0.001 |
Variabales . | AIP . | USW . | P value . | Variables . | AIP . | USW . | P value . |
---|---|---|---|---|---|---|---|
Reported cases | 1.3% | 1.5% | NS | Stage IV | 37% | 29% | <0.01 |
Median age in yr | 31 | 38 | <0.01 | 1 year survival | 81% | 75% | <0.01 |
Age < 35 at diagnosis | 62% | 51% | <0.001 | 2 years survival | 79% | 66% | <0.001 |
Age > 35 at diagnosis | 38% | 49% | <0.001 | 3 years survival | 72% | 61% | <0.001 |
Stage I/II | 20% | 35% | <0.001 | 4 years survival | 68% | 57% | =0.001 |
Stage III | 43% | 36% | <0.001 | 5 years survival | 66% | 53% | =0.001 |
Variables . | AIP . | USW . | P value . | Variables . | AIP . | USW . | P value . |
---|---|---|---|---|---|---|---|
Reported cases | <1% | <1% | NS | 1 yr survival | 48% | 32% | <0.001 |
Cases in male | 61% | 59% | NS | 2 yrs survival | 27% | 18% | <0.001 |
Cases in female | 39% | 49% | NS | 3 yrs survival | 22% | 15% | <0.001 |
Median age in yr | 42 | 56 | <0.001 | 4 yrs survival | 18% | 11% | <0.001 |
Poor prognostic factors | 67% | 64% | NS | 5 yrs survival | 15% | 8% | <0.001 |
Variables . | AIP . | USW . | P value . | Variables . | AIP . | USW . | P value . |
---|---|---|---|---|---|---|---|
Reported cases | <1% | <1% | NS | 1 yr survival | 48% | 32% | <0.001 |
Cases in male | 61% | 59% | NS | 2 yrs survival | 27% | 18% | <0.001 |
Cases in female | 39% | 49% | NS | 3 yrs survival | 22% | 15% | <0.001 |
Median age in yr | 42 | 56 | <0.001 | 4 yrs survival | 18% | 11% | <0.001 |
Poor prognostic factors | 67% | 64% | NS | 5 yrs survival | 15% | 8% | <0.001 |
Variables . | AIP . | USW . | P value . | Variables . | AIP . | USW . | P value . |
---|---|---|---|---|---|---|---|
Reported cases | 1.3% | 1.2% | NS | 1 yr survival | 52% | 34% | <0.001 |
Cases in male | 51% | 55% | NS | 2 yrs survival | 36% | 22% | <0.001 |
Cases in female | 49% | 45% | NS | 3 yrs survival | 34% | 17% | <0.001 |
Median age in yr | 54 | 67 | <0.001 | 4 yrs survival | 30% | 15% | <0.001 |
Poor prognostic factors | 62% | 65% | NS | 5 yrs survival | 29% | 14% | <0.001 |
Variables . | AIP . | USW . | P value . | Variables . | AIP . | USW . | P value . |
---|---|---|---|---|---|---|---|
Reported cases | 1.3% | 1.2% | NS | 1 yr survival | 52% | 34% | <0.001 |
Cases in male | 51% | 55% | NS | 2 yrs survival | 36% | 22% | <0.001 |
Cases in female | 49% | 45% | NS | 3 yrs survival | 34% | 17% | <0.001 |
Median age in yr | 54 | 67 | <0.001 | 4 yrs survival | 30% | 15% | <0.001 |
Poor prognostic factors | 62% | 65% | NS | 5 yrs survival | 29% | 14% | <0.001 |
Variables . | AIP . | USW . | P value . | Variables . | AIP . | USW . | P value . |
---|---|---|---|---|---|---|---|
Reported cases | <1% | <1% | NS | 1 yr survival | 94% | 87% | <0.01 |
Cases in male | 67% | 65% | NS | 2 yrs survival | 87% | 78% | <0.01 |
Cases in female | 33% | 35% | NS | 3 yrs survival | 79% | 71% | <0.01 |
Median age in yr | 64 | 72 | <0.01 | 4 yrs survival | 73% | 65% | <0.01 |
Poor prognostic factors | 49% | 45% | NS | 5 yrs survival | 66% | 58% | <0.01 |
Variables . | AIP . | USW . | P value . | Variables . | AIP . | USW . | P value . |
---|---|---|---|---|---|---|---|
Reported cases | <1% | <1% | NS | 1 yr survival | 94% | 87% | <0.01 |
Cases in male | 67% | 65% | NS | 2 yrs survival | 87% | 78% | <0.01 |
Cases in female | 33% | 35% | NS | 3 yrs survival | 79% | 71% | <0.01 |
Median age in yr | 64 | 72 | <0.01 | 4 yrs survival | 73% | 65% | <0.01 |
Poor prognostic factors | 49% | 45% | NS | 5 yrs survival | 66% | 58% | <0.01 |
Variables . | AIP . | USW . | P value . | Variables . | AIP . | USW . | P value . |
---|---|---|---|---|---|---|---|
Reported cases | <1% | <1% | NS | 1 yr survival | 85% | 71% | <0.001 |
Cases in male | 65% | 66% | NS | 2 yrs survival | 83% | 56% | <0.001 |
Cases in female | 35% | 34% | NS | 3 yrs survival | 80% | 46% | <0.001 |
Median age in yr | 57 | 66 | <0.001 | 4 yrs survival | 74% | 38% | <0.001 |
Poor prognostic factors | 31% | 29% | NS | 5 yrs survival | 71% | 32% | <0.001 |
Variables . | AIP . | USW . | P value . | Variables . | AIP . | USW . | P value . |
---|---|---|---|---|---|---|---|
Reported cases | <1% | <1% | NS | 1 yr survival | 85% | 71% | <0.001 |
Cases in male | 65% | 66% | NS | 2 yrs survival | 83% | 56% | <0.001 |
Cases in female | 35% | 34% | NS | 3 yrs survival | 80% | 46% | <0.001 |
Median age in yr | 57 | 66 | <0.001 | 4 yrs survival | 74% | 38% | <0.001 |
Poor prognostic factors | 31% | 29% | NS | 5 yrs survival | 71% | 32% | <0.001 |
Our analysis shows that AIP are diagnosed with common hematological malignancies at a younger age than USW. The distribution of these malignancies according to gender follows other major groups but there is no statistical difference in age at diagnosis, stages, tumor biology, treatment methodologies or survival between male and female AIP. Noticeable better 1-5 years survival could be attributed to difference in tumor biology, cytogenetics, emigrational factors, higher socioeconomic status, better access to health care, educational background with awareness and environmental factors. Future studies are warranted to examine the behavior and biology of tumor in this population.
No relevant conflicts of interest to declare.
Author notes
Asterisk with author names denotes non-ASH members.